Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Xilio Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 700,000 options to buy @ $2.785, valued at $1.9M
08/18/2023 4 Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 300,000 options to buy @ $2.785, valued at $835.5k
08/18/2023 4 Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 25,000 options to buy @ $2.785, valued at $69.6k
08/18/2023 4 Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 136,500 options to buy @ $2.785, valued at $380.2k
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Investor presentation, Quarterly results
08/07/2023 4 Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 150,000 options to buy @ $2.75, valued at $412.5k
08/07/2023 3 Frankenfield Christopher James (COO) has filed a Form 3 on Xilio Therapeutics, Inc.
08/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SECOND AMENDED AND RESTATED EMPLOYMENT"
05/25/2023 8-K Investor presentation
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/03/2023 4 Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 55,000 options to buy @ $3.17, valued at $174.4k
04/03/2023 3 Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 3 on Xilio Therapeutics, Inc.
04/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
02/09/2023 SC 13G/A FMR LLC reports a 6.9% stake in XILIO THERAPEUTICS INC
01/25/2023 SC 13G Octagon Capital Advisors LP reports a 8.8% stake in XILIO THERAPEUTICS, INC.
01/09/2023 8-K Investor presentation
01/04/2023 4 Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 350,000 options to buy @ $2.69, valued at $941.5k
01/04/2023 4 Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 136,500 options to buy @ $2.69, valued at $367.2k
01/04/2023 4 English Edward C (PRINCIPAL ACCOUNTING OFFICER) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns: Granted 24,000 options to buy @ $2.69, valued at $64.6k
12/29/2022 SC 13G/A Flynn James E reports a 0% stake in Xilio Therapeutics, Inc.
11/21/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/16/2022 3 English Edward C (Principal Accounting Officer) has filed a Form 3 on Xilio Therapeutics, Inc.
11/14/2022 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in XILIO THERAPEUTICS, INC.
11/09/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Investor presentation, Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy